HC Wainwright & Co. Initiates Coverage On Prime Medicine With Buy Rating, Announces Price Target of $10
HC Wainwright & Co. Initiates Coverage On Prime Medicine With Buy Rating, Announces Price Target of $10
HC Wainwright & Co.以買入評級啓動Prime Medicine的保險，宣佈目標股價爲10美元
HC Wainwright & Co. analyst Arthur He initiates coverage on Prime Medicine (NASDAQ:PRME) with a Buy rating and announces Price Target of $10.
HC Wainwright & Co. 分析師亞瑟·何以買入評級啓動了對Prime Medicine（納斯達克股票代碼：PRME）的報道，並宣佈目標股價爲10美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。